Mavacamten granted Breakthrough Therapy Designation


MyoKardia has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy.

The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

“Receipt of Breakthrough Therapy Designation from the FDA acknowledges both the significant unmet need among patients with obstructive hypertrophic cardiomyopathy, for whom there are currently no targeted therapies, and the highly encouraging clinical results generated by mavacamten.  We look forward to working closely with the FDA in pursuit of regulatory approval so that we may bring mavacamten to people with HCM and remain appreciative of the collaborative approach and valued input the agency has provided throughout mavacamten’s development,” said Tassos Gianakakos, CEO of MyoKardia.

In May, MyoKardia announced topline results from the company’s pivotal Phase 3 EXPLORER clinical trial of mavacamten for the treatment of symptomatic patients with obstructive HCM. Mavacamten was well tolerated, with a safety profile comparable to placebo, and demonstrated a robust treatment effect, with patients experiencing clinically meaningful responses to treatment, including reductions in symptoms, improvements in cardiac function and reduction or elimination of the obstruction of the left ventricle.

MyoKardia is currently preparing a New Drug Application (NDA) for mavacamten, with plans to submit to the FDA in the first quarter of 2021.


Please enter your comment!
Please enter your name here